Drugs and patents in ATC class S01AX

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
AVAGARD	alcohol; chlorhexidine gluconate
EXIDINE	chlorhexidine gluconate
CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate
READYPREP CHG	chlorhexidine gluconate
PAROEX	chlorhexidine gluconate
>Tradename	>Generic Name

Last updated: February 19, 2026

The global market for topical anti-infectives, specifically within the ATC classification S01AX (Other anti-infectives), is characterized by a mature but evolving patent landscape. While broad-spectrum antibiotics have historically dominated, there is increasing patent activity around novel formulations, combination therapies, and agents targeting resistant bacterial strains and viral infections. Key players are focusing on extending product lifecycles through formulation patents and exploring new therapeutic areas, such as ophthalmic antivirals and antifungals.

What are the Key Market Drivers for S01AX Anti-infectives?

The S01AX classification encompasses topical anti-infectives used for ocular, otic, and dermatological conditions. Several factors drive market growth and innovation:

Increasing prevalence of infections:
- Bacterial conjunctivitis remains a common ophthalmological condition, leading to consistent demand for topical antibiotics.
- Otic infections, such as otitis externa, also contribute to the sustained need for anti-infective ear drops.
- Skin and soft tissue infections (SSTIs) are prevalent, with a significant portion treated topically.
Rise of antimicrobial resistance (AMR): The growing threat of AMR fuels research and development into new anti-infective agents and novel delivery systems to overcome resistance mechanisms. This includes the development of agents with novel mechanisms of action and those targeting specific resistant pathogens.
Aging global population: Elderly individuals are often more susceptible to infections, increasing the demand for anti-infective treatments. Age-related conditions can also compromise immune defenses, necessitating effective topical therapies.
Technological advancements in drug delivery: Innovations in formulation technologies, such as sustained-release systems, liposomes, and nanoparticle-based delivery, aim to improve efficacy, reduce dosing frequency, and minimize side effects. These advancements are frequently the subject of patent applications.
Growing healthcare expenditure in emerging economies: As healthcare access and spending increase in developing regions, the demand for prescription and over-the-counter anti-infectives rises.
Preference for topical administration: Topical administration offers advantages like direct drug delivery to the site of infection, reduced systemic exposure, and potentially fewer side effects compared to systemic treatments. This preference supports the market for S01AX agents.
Expansion into new indications: Research into the use of S01AX agents for less common or emerging infectious conditions, including certain fungal and viral infections in topical applications, is a driver for novel patentable compositions and uses.

What is the Current Patent Landscape for S01AX Anti-infectives?

The patent landscape for S01AX anti-infectives is a complex web of composition of matter patents, formulation patents, method of use patents, and process patents. Key trends and characteristics include:

Dominance of established active pharmaceutical ingredients (APIs): Many S01AX products utilize well-established APIs such as moxifloxacin, gatifloxacin, ciprofloxacin, ofloxacin, tobramycin, and gentamicin. Patent protection for these older APIs has largely expired or is nearing expiration.
Focus on formulation and delivery patents: To extend product lifecycles and differentiate in a crowded market, companies are heavily investing in patenting novel formulations. This includes:
- Preservative-free formulations: Addressing concerns about ocular surface toxicity and patient sensitivity.
- Improved viscosity and mucoadhesion: Enhancing residence time at the target site.
- Nanoparticle or liposomal delivery systems: Improving drug penetration and sustained release.
- Combination therapies: Developing fixed-dose combinations of different anti-infectives or anti-infectives with anti-inflammatory agents to broaden spectrum of activity and combat resistance.
Emergence of antiviral and antifungal patents: While historically dominated by antibacterials, there is growing patent activity around topical antiviral agents for ocular infections (e.g., herpes simplex keratitis) and topical antifungals for dermatological and ocular mycoses.
Geographic patent filing strategies: Filings are concentrated in major pharmaceutical markets such as the United States, Europe (via the European Patent Office), Japan, China, and India. Companies seek to protect their innovations in regions with significant market potential and robust intellectual property frameworks.
Key patent holders: Major pharmaceutical companies with significant ophthalmology, dermatology, and infectious disease portfolios hold a substantial number of patents in this space. These include companies like Alcon, Bausch Health, Pfizer, Santen Pharmaceutical, and various generic manufacturers actively pursuing patent challenges or developing bioequivalent formulations.
Patent litigation and challenges: As patents approach expiration or for newly developed formulations of older drugs, patent litigation is common. Generic manufacturers often challenge existing patents to pave the way for market entry.
Orphan drug designations: For rare ocular or dermatological infections, orphan drug designations can provide market exclusivity extensions beyond standard patent terms, influencing strategic patenting.

Notable Patent Trends and Examples

Moxifloxacin formulations: Patents have been filed for various preservative-free moxifloxacin ophthalmic solutions, aiming to improve patient comfort and safety. For example, the formulation of Vigamox (moxifloxacin hydrochloride ophthalmic solution) by Alcon has been subject to numerous patent applications and lifecycle management strategies.
Combination products: Patents protecting fixed-dose combinations like tobramycin/dexamethasone or ciprofloxacin/dexamethasone are prevalent for treating bacterial infections with associated inflammation.
Novel antibacterial agents: While less common for broad topical use, patents for new classes of topical antibiotics with specific activity against resistant Gram-positive or Gram-negative bacteria are being pursued.
Ophthalmic antivirals: Patents related to ganciclovir ophthalmic gel or trifluridine ophthalmic solutions for treating herpetic keratitis represent a growing segment.
Topical antifungals: Patents for agents like econazole, miconazole, and newer azole derivatives for dermatophytosis and candidiasis, as well as for fungal keratitis, continue to be filed.

What are the Regulatory Considerations Impacting S01AX Patents?

Regulatory pathways significantly influence the patentability and market exclusivity of S01AX anti-infectives.

U.S. Food and Drug Administration (FDA):
- Orange Book: The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (often referred to as the Orange Book) lists patents and exclusivity data for approved drugs. This is a critical resource for understanding patent protection status and potential generic entry.
- Hatch-Waxman Act: This legislation governs the process for generic drug approval and patent challenges. It provides mechanisms for brand-name manufacturers to list patents and for generic manufacturers to challenge them.
- New Chemical Entity (NCE) exclusivity: A new molecular entity can receive up to five years of market exclusivity, during which generic applications cannot be approved.
- New Use/Formulation exclusivity: For significant new uses or formulations of existing drugs, up to three years of exclusivity can be granted. This is a key strategy for S01AX products.
European Medicines Agency (EMA):
- Data exclusivity: Upon marketing authorization, new medicinal products generally benefit from eight years of data exclusivity, during which generic applications cannot be submitted.
- Market exclusivity: Following data exclusivity, an additional two years of market exclusivity is granted, during which generics cannot be marketed. This can be extended by one year in certain circumstances.
- Supplementary Protection Certificates (SPCs): SPCs can extend patent protection for up to five years to compensate for the time lost due to regulatory approval processes.
Patent Term Extension (PTE): In the U.S. and other jurisdictions, patent terms can be extended to compensate for patent term lost due to regulatory review periods, subject to specific limitations.
Orphan Drug Exclusivity: For drugs designated as orphan drugs (treating rare diseases), longer periods of market exclusivity are granted (e.g., seven years in the U.S., ten years in Europe).

These regulatory frameworks directly interact with patent protection, creating complex strategic considerations for R&D and market entry planning for S01AX anti-infectives.

What are the Key Challenges and Opportunities in the S01AX Segment?

The S01AX segment presents both significant challenges and promising opportunities for innovation and market participants.

Challenges:

Increasing antimicrobial resistance: This is the most significant challenge, necessitating continuous innovation to develop agents effective against resistant strains. The efficacy of many older topical antibiotics is being compromised.
Pricing pressures and reimbursement: Market access and reimbursement can be challenging, particularly for newer, more expensive formulations or novel agents. Generic competition for off-patent molecules intensifies pricing pressure.
Regulatory hurdles for novel agents: Developing entirely new classes of topical anti-infectives is costly and time-consuming, with stringent regulatory requirements for safety and efficacy.
Limited pipeline for truly novel topical antibiotics: The discovery of new classes of antibiotics has slowed, making it difficult to bring fundamentally new topical antibacterial agents to market.
Patient adherence and administration difficulties: For some patients, applying topical treatments correctly and consistently can be a barrier to effective treatment.
Competition from systemic treatments: While topical treatments are preferred for localized infections, severe or widespread infections may necessitate systemic therapy, limiting the market for some topical agents.

Opportunities:

Development of next-generation antibiotics: Research into novel antibacterial mechanisms, bacteriophages, and antimicrobial peptides offers potential for new S01AX agents.
Advanced drug delivery systems: Innovations in nanotechnology, targeted delivery, and sustained-release formulations can improve efficacy, reduce side effects, and enhance patient compliance.
Combination therapies: Developing synergistic combinations of existing or novel anti-infectives, or combining anti-infectives with anti-inflammatory or immunomodulatory agents, can offer broader spectrum activity and combat resistance.
Targeting specific resistant pathogens: Developing topical agents specifically designed to combat prevalent resistant strains like MRSA (Methicillin-resistant Staphylococcus aureus) or resistant Gram-negative bacteria in ocular or dermatological settings.
Expanding indications: Identifying and developing topical anti-infective treatments for emerging or under-addressed viral and fungal infections in ophthalmic and dermatological practice.
Biologics and biosimil development: While less common in S01AX currently, the broader trend in biologics could eventually influence topical anti-infective development, particularly for complex indications or to bypass antibiotic resistance.
Personalized medicine approaches: Tailoring topical anti-infective therapy based on pathogen susceptibility testing and patient-specific factors.

Key Takeaways

The S01AX anti-infective market is driven by persistent infection rates and the growing threat of antimicrobial resistance. Patent strategies are shifting from protecting active pharmaceutical ingredients to focusing on innovative formulations, delivery systems, and combination therapies, primarily to extend product lifecycles and differentiate in a competitive landscape. Regulatory frameworks, including FDA and EMA guidelines, alongside patent term extensions and exclusivity provisions, significantly shape market exclusivity and generic entry. While challenges such as AMR and pricing pressures persist, opportunities lie in developing next-generation agents, advanced drug delivery, and novel therapeutic combinations to address unmet medical needs in topical anti-infective care.

Frequently Asked Questions

Which specific pathogens are targeted by the majority of S01AX anti-infectives currently patented? The majority of S01AX anti-infectives with extensive patent coverage target common bacterial pathogens, including Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae for ophthalmic and otic applications. Dermatological applications also frequently target Staphylococcus epidermidis, Propionibacterium acnes, and various dermatophytes.
What is the typical duration of patent protection for a novel formulation of an existing S01AX drug? A novel formulation of an existing S01AX drug typically benefits from the remaining term of the original composition of matter patent, plus potential patent term extensions (PTE) in jurisdictions like the U.S. and supplementary protection certificates (SPCs) in Europe, which can add up to five years. Additionally, the regulatory exclusivity granted by agencies like the FDA (e.g., 3-year exclusivity for new formulations) runs concurrently with patent protection.
Are there significant patent filings for anti-infectives targeting viral infections within the S01AX classification? Yes, there are significant patent filings for anti-infectives targeting viral infections within or adjacent to the S01AX classification, particularly for ophthalmic applications. Examples include patents for trifluridine, ganciclovir, and acyclovir derivatives used to treat herpetic keratitis.
How does the rise of antimicrobial resistance impact the patentability of new S01AX agents? The rise of antimicrobial resistance (AMR) enhances the patentability of new S01AX agents by demonstrating a clear unmet medical need. Patents can be obtained for novel compounds with unique mechanisms of action that overcome existing resistance, for formulations that improve penetration through biofilms or resistant bacterial cell walls, and for methods of treating infections caused by specific resistant pathogens. Demonstrating efficacy against multi-drug resistant organisms is a strong basis for patent claims.
What is the strategic importance of preservative-free formulations in S01AX patenting? Preservative-free formulations are strategically important in S01AX patenting due to their improved safety profile, particularly for ocular applications. Many traditional preservatives can cause ocular surface toxicity and irritation. Patents covering novel preservative-free compositions offer advantages in patient compliance, reduced adverse effects, and can create a distinct market segment even for established APIs, thereby extending product exclusivity and market value.

Cited Sources

[1] World Health Organization. (2020). Antimicrobial resistance: an urgent public health threat. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance [2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book [3] European Medicines Agency. (n.d.). Medicines legislation. https://www.ema.europa.eu/en/about-ema/our-work/medicines-legislation [4] U.S. Patent and Trademark Office. (n.d.). Patent Laws and Regulations. https://www.uspto.gov/web/offices/pac/mpep/laws_and_rules.html [5] European Patent Office. (n.d.). EPO's role. https://www.epo.org/about-us/mission/role.html

Drugs in ATC Class S01AX

Drugs in ATC Class: S01AX - Other antiinfectives

S01AX Anti-infectives Market Dynamics and Patent Landscape